Evidence mapPaperPMID 42550412Full record

ArticleClinical and experimental nephrology2026

Dose-dependent association of depression with incidence of end-stage kidney disease and all-cause mortality, CKD-JAC study: a retrospective cohort study.

Maki Shinzawa, Kenta Murotani, Takahiro Imaizumi, Ryohei Yamamoto, Yoshitaka Isaka, Takashi Wada, Shoichi Maruyama

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical and experimental nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Maki ShinzawaHealth and Counseling Center, The University of Osaka, 1-17 Machikaneyama-cyo, Toyonaka, Osaka, 560-0043, Japan. shinzawa@kid.med.osaka-u.ac.jp.ORCID http://orcid.org/0000-0002-7739-893X
Kenta MurotaniSchool of Medical Technology, Kurume University, Kurume, Japan.
Takahiro ImaizumiDepartment of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.
Ryohei YamamotoHealth and Counseling Center, The University of Osaka, 1-17 Machikaneyama-cyo, Toyonaka, Osaka, 560-0043, Japan.
Yoshitaka IsakaDepartment of Nephrology, The University of Osaka Graduate School of Medicine, Suita, Japan.
Takashi WadaDepartment of Nephrology and Rheumatology, Kanazawa University, Kanazawa, Japan.
Shoichi MaruyamaDepartment of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough depression is common among patients with chronic kidney disease (CKD), its impact on the incidence of end-stage kidney disease (ESKD) and all-cause mortality remains unclear.

methodsThis retrospective cohort study used Cox proportional hazards (CPH) models and CPH models with penalized splines to assess the association between depression severity and the incidence of ESKD and mortality in patients with CKD, drawing on data from the Chronic Kidney Disease Japan Cohort (CKD-JAC) Study.

resultsThis study included 1,694 patients with CKD (median age 61 years; mean eGFR 29.0 ± 12.2 mL/min/1.73 m

conclusionDepression severity showed dose-dependent associations with increased the incidence of ESKD and mortality in patients with CKD. Although mortality risk was significantly higher in the moderate and severe groups (BDI-II score ≥ 20), the stepwise elevation in ESKD risk did not reach statistical significance, and an optimal threshold for ESKD risk could not be identified.

Indexed as

All-cause mortalityDepressionEnd-stage kidney disease

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.